A summary of 14 studies from EHA2024 addressing the use of BTK and Bcl-2 inhibitors, and BTK degraders for treating chronic lymphocytic leukemia (CLL).

Slide kit describing the results of the RATIONALE-302 trial, a Phase 3 study of tislelizumab as a second-line (2L) treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma (ESCC).

Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

Slide kit outlining the long-term follow-up of the ASPEN trial: Zanubrutinib vs. ibrutinib in patients with Waldenström’s macroglobulinemia (WM).

Primary analysis of the ROSEWOOD trial – zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory (R/R) follicular lymphoma (FL).